Actively Recruiting
Links Between Cognitive Deficits During Normal or Pathological Aging and Slow Waves Measured in EEG
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-04-13
90
Participants Needed
1
Research Sites
101 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
With age, memory processes (encoding, consolidation and retrieval) as well as daytime vigilance are altered. Sleep is also impaired in older adults, notably slow waves that are known to play a key role in memory consolidation. Interestingly, some slow waves can also be detected in EEG recordings during wakefulness, and have been related to vigilance fluctuations. The investigators believe that slow waves, during both sleep and wakefulness, could constitute a common biomarker of sleep disturbances and daytime vigilance problems. A dysregulation of slow waves could thus explain the impact of aging on the different memory processes. Since alterations in memory capacity, attention, and sleep quality are further exacerbated in patients with Alzheimer's disease (AD), the investigators propose to study the links between aging (normal and pathological), sleep and daytime vigilance alterations, and their impacts on the different key stages of memory. The investigators will examine the associations between slow waves and changes in memory and vigilance in normal and pathological aging by studying young adults, seniors without cognitive disorders, and patients with prodromal AD. By replaying sensory cues associated with learning material during sleep, the investigators will also evaluate the effectiveness of auditory stimulation during sleep to enhance memory consolidation in older adults without and without cognitive deficits. Overall, this study aims to better understand the relationships between slow waves, aging, memory, and vigilance, providing insights into cognitive decline and potential interventions in aging and Alzheimer's disease.
CONDITIONS
Official Title
Links Between Cognitive Deficits During Normal or Pathological Aging and Slow Waves Measured in EEG
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female
- Signed informed consent
- Affiliated with a social security system
- Native French speaker
- Completed at least 7 years of schooling (minimum 9th grade level)
- Patients aged 60 to 85 years with prodromal Alzheimer's disease diagnosed by clinical phenotype and biological markers (lumbar puncture, amyloid PET, or positive plasma biomarkers)
- Cognitively healthy seniors aged 60 to 85 years matched by age and sex with patients, with MMSE score 26, BREF score 16, and 5-word test score 8
- Young adults aged 18 to 35 years matched by sex with patients, cognitively healthy with MMSE 26, BREF 16, and 5-word test 8
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Maladies du Sommeil
Paris, France, 75013
Actively Recruiting
Research Team
M
Marc Teichmann, MD
CONTACT
P
Pierre Champetier, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here